KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Current Deferred Revenue: 2009-2025

Historic Current Deferred Revenue for Idexx Laboratories (IDXX) over the last 16 years, with Sep 2025 value amounting to $35.7 million.

  • Idexx Laboratories' Current Deferred Revenue fell 7.13% to $35.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.7 million, marking a year-over-year decrease of 7.13%. This contributed to the annual value of $33.8 million for FY2024, which is 9.13% down from last year.
  • According to the latest figures from Q3 2025, Idexx Laboratories' Current Deferred Revenue is $35.7 million, which was down 1.74% from $36.3 million recorded in Q2 2025.
  • Idexx Laboratories' 5-year Current Deferred Revenue high stood at $41.6 million for Q1 2021, and its period low was $33.8 million during Q4 2024.
  • For the 3-year period, Idexx Laboratories' Current Deferred Revenue averaged around $36.9 million, with its median value being $37.3 million (2023).
  • As far as peak fluctuations go, Idexx Laboratories' Current Deferred Revenue grew by 13.25% in 2021, and later decreased by 9.13% in 2024.
  • Quarterly analysis of 5 years shows Idexx Laboratories' Current Deferred Revenue stood at $40.0 million in 2021, then decreased by 5.24% to $37.9 million in 2022, then decreased by 1.96% to $37.2 million in 2023, then fell by 9.13% to $33.8 million in 2024, then declined by 7.13% to $35.7 million in 2025.
  • Its Current Deferred Revenue was $35.7 million in Q3 2025, compared to $36.3 million in Q2 2025 and $35.0 million in Q1 2025.